Volcano Corp. blew away analysts' forecasts for the 4th quarter and full-year 2011, but aims low for this year.
Volcano Corp. (NSDQ:VOLC) blew away analysts' expectations for the 4th quarter and 2011, but lost some love on Wall Street over its low guidance for 2012.
The San Diego-based company reported a 14% bump in sales to $92.7 million, compared to $81.2 million for the same period in 2010, and $29.4 million in profit, compared to a loss of $1.7 million during Q4 2010. That translates to 54 cents EPS – 14 cents EPS on an adjusted basis, nearly triple analysts' expectations of 5 cents apiece.
Volcano raked in $343.5 million in revenues for 2011, a 17% jump over $294.1 million in 2010, driven by a 23% bump for its medical products segment. Volcano's industrial segment posted a 52% sales decline.
Full-year earnings soared to $38.1 million, or 70 cents per diluted share, up a whopping 633% over $5.2 million, or 10 cents per diluted share, during 2010.
Although adjusted EPS for 2011 was bolstered by 40 cents due to the release of a portion of the company's deferred tax valuation allowance in the 4th quarter, adjusted EPS of 30 cents still beat analysts' full-year expectations of 21 cents.
Volcano attributed the spike primarily to a 37% bump in fractional flow reserve disposable revenues and an equally significant 19% jump in intravascular ultrasound disposable revenues.
The company forecast its 2012 earnings in the range of $392 million to $399 million, or 21-24 cents EPS, falling short of analysts' prediction of 30 cents for next year.
VOLC shares slid a bit on The Street following its after-market-close release. Shares opened at $25.52 this morning before regaining ground to trade at $27.87 as of about 1:00 p.m. today – still a 1% drop from last night's $28.18 close.
Pulmonx taps former Asthmatx CEO Glen French to be its new chief executive.
Here's a look at some of the top legal news stories for medical device companies this week: InSightec...
The U.S. says it hammered out a deal with China to speed American-made medical devices and drugs to...
Delcath Systems adds 2 German research centers to a Phase II clinical trial of its Chemosat...
The FDA awards priority review status to Cohera Medical's surgical sealant Sylys because the product...